Monitor for updates on clinical trial progress and pipeline advancement; assess whether the capital deployment leads to value-accretive milestones. Watch for insider trading activity and future financing needs.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 13 $77.86entry
- T+1 · 8mo ago +0.18%α −0.84% · $78.00
- T+5 · 8mo ago −0.13%α +1.99% · $77.76
- T+20 · 7mo ago +15.59%α +12.00% · $90.00
- T+60 · 5mo ago +4.32%α −7.30% · $81.22
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Dianthus Therapeutics raised approximately $719 million in gross proceeds through a public offering of 8.47 million common shares and pre-funded warrants for 402,468 additional shares, priced at $81.00 per share. The capital will fund clinical development, commercial readiness, and general corporate purposes, extending the company's runway but increasing potential dilution for existing shareholders.
Key Financial Metrics
Key Facts
- Closed public offering of 8,470,989 common shares and pre-funded warrants for 402,468 shares
- Offering price: $81.00 per share; pre-funded warrants priced at $80.999 with $0.001 exercise price
- Aggregate gross proceeds: ~$719 million before expenses
- Proceeds to fund clinical and preclinical programs, commercial readiness, and general corporate use
- Joint book-runners include Jefferies, TD Cowen, Evercore ISI, Stifel, Guggenheim, and William Blair
Financial Impact
$719 million gross proceeds, significant capital raise with moderate dilution
Risk Factors
- Dilution to existing shareholders from new share issuance and potential warrant exercises
- Execution risk in clinical development and uncertain regulatory pathways for pipeline assets
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3255079 |
Track record
23 reports on DNTH
7 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +41.40% at T+60 after the Jun 11, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $89.76 Now $89.55 −0.23% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 3/10 Entry $88.81 to $89.30 Now $89.55 +0.83% ▲ +0.55% −0.77% vs SPY
- Nov 4, 202612d ago 8-K Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $83.01 to $86.03 Now $89.55 +7.88% ▲ +3.64% +3.33% vs SPY
- Oct 30, 202617d ago Institutional Cluster Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
- Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $81.57 to $77.58 Now $89.55 +9.78% ▼ −4.89% −4.88% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 4/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers